Healthcare Global Enterprises Limited — PPTs, 12-11-2025: Investor Presentation

HCG reported solid Q2FY26 results: Revenue jumped 16.9% YoY to 647 Cr, and Adjusted EBITDA grew 18.4% YoY to 123.3 Cr, boosting margins to 19.1%. Half-year figures also show robust growth, with Revenue at 1,260.1 Cr (+16.8%) and Adjusted EBITDA at 235.2 Cr (+19.3%).

Growth was primarily driven by HCG's cancer care centers, particularly strong performance in Maharashtra, Gujarat, East India, Andhra Pradesh, and Africa due to clinician additions, expanded capacity, and higher patient volumes. Milann (fertility) revenue saw a slight decline.

The company recently shifted its Ahmedabad cancer center to a larger facility, adding 100 beds, and is introducing advanced Tomo-therapy in Vizag. Total operational beds increased significantly. HCG is actively investing in new centers in North Bangalore and Whitefield, expanding its footprint.

Despite strong operational metrics, Profit After Tax for Q2 fell 9.6% to 16.3 Cr (H1 down 30.1% to 21 Cr) due to higher depreciation and interest costs from recent growth investments and acquisitions. The company maintains significant capacity headroom, signaling future growth potential.